vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and NORTHERN TECHNOLOGIES INTERNATIONAL CORP (NTIC). Click either name above to swap in a different company.
AbCellera Biologics Inc. is the larger business by last-quarter revenue ($44.9M vs $23.3M, roughly 1.9× NORTHERN TECHNOLOGIES INTERNATIONAL CORP). NORTHERN TECHNOLOGIES INTERNATIONAL CORP runs the higher net margin — 1.0% vs -19.9%, a 21.0% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 9.2%). NORTHERN TECHNOLOGIES INTERNATIONAL CORP produced more free cash flow last quarter ($-479.7K vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 5.8%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Maxar Technologies Inc., was an American space technology company, specializing in geospatial intelligence, Earth observation, and on-orbit satellite servicing, satellite products, and related services. DigitalGlobe and MDA Holdings Company merged to become Maxar Technologies on October 5, 2017.
ABCL vs NTIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $23.3M |
| Net Profit | $-8.9M | $237.8K |
| Gross Margin | — | 36.0% |
| Operating Margin | -63.7% | 4.0% |
| Net Margin | -19.9% | 1.0% |
| Revenue YoY | 788.4% | 9.2% |
| Net Profit YoY | 73.9% | -57.6% |
| EPS (diluted) | $-0.03 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $23.3M | ||
| Q3 25 | $9.0M | $22.3M | ||
| Q2 25 | $17.1M | $21.5M | ||
| Q1 25 | $4.2M | $19.1M | ||
| Q4 24 | $5.0M | $21.3M | ||
| Q3 24 | $6.5M | $23.3M | ||
| Q2 24 | $7.3M | $20.7M | ||
| Q1 24 | $10.0M | $20.8M |
| Q4 25 | $-8.9M | $237.8K | ||
| Q3 25 | $-57.1M | $-1.1M | ||
| Q2 25 | $-34.7M | $121.8K | ||
| Q1 25 | $-45.6M | $434.3K | ||
| Q4 24 | — | $561.1K | ||
| Q3 24 | $-51.1M | $1.8M | ||
| Q2 24 | $-36.9M | $976.6K | ||
| Q1 24 | $-40.6M | $1.7M |
| Q4 25 | — | 36.0% | ||
| Q3 25 | — | 37.9% | ||
| Q2 25 | — | 38.4% | ||
| Q1 25 | — | 35.6% | ||
| Q4 24 | — | 38.3% | ||
| Q3 24 | — | 43.8% | ||
| Q2 24 | — | 38.2% | ||
| Q1 24 | — | 40.0% |
| Q4 25 | -63.7% | 4.0% | ||
| Q3 25 | -851.8% | 4.2% | ||
| Q2 25 | -290.2% | 4.0% | ||
| Q1 25 | -1479.6% | -1.7% | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | -1439.4% | 11.8% | ||
| Q2 24 | -1276.2% | 7.4% | ||
| Q1 24 | -551.5% | 10.6% |
| Q4 25 | -19.9% | 1.0% | ||
| Q3 25 | -637.8% | -4.9% | ||
| Q2 25 | -203.3% | 0.6% | ||
| Q1 25 | -1077.2% | 2.3% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | -785.4% | 7.9% | ||
| Q2 24 | -504.3% | 4.7% | ||
| Q1 24 | -408.0% | 8.2% |
| Q4 25 | $-0.03 | $0.03 | ||
| Q3 25 | $-0.19 | $-0.11 | ||
| Q2 25 | $-0.12 | $0.01 | ||
| Q1 25 | $-0.15 | $0.04 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | $-0.17 | $0.19 | ||
| Q2 24 | $-0.13 | $0.10 | ||
| Q1 24 | $-0.14 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $6.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $72.4M |
| Total Assets | $1.4B | $104.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $6.4M | ||
| Q3 25 | $83.2M | $7.3M | ||
| Q2 25 | $92.4M | $6.8M | ||
| Q1 25 | $159.3M | $5.1M | ||
| Q4 24 | $156.3M | $5.6M | ||
| Q3 24 | $126.6M | $5.0M | ||
| Q2 24 | $148.3M | $5.8M | ||
| Q1 24 | $123.6M | $4.8M |
| Q4 25 | $966.9M | $72.4M | ||
| Q3 25 | $964.0M | $72.1M | ||
| Q2 25 | $1.0B | $72.4M | ||
| Q1 25 | $1.0B | $69.7M | ||
| Q4 24 | $1.1B | $70.2M | ||
| Q3 24 | $1.1B | $71.2M | ||
| Q2 24 | $1.1B | $68.9M | ||
| Q1 24 | $1.1B | $68.4M |
| Q4 25 | $1.4B | $104.0M | ||
| Q3 25 | $1.4B | $102.7M | ||
| Q2 25 | $1.4B | $99.3M | ||
| Q1 25 | $1.3B | $93.7M | ||
| Q4 24 | $1.4B | $94.0M | ||
| Q3 24 | $1.4B | $94.7M | ||
| Q2 24 | $1.4B | $89.3M | ||
| Q1 24 | $1.5B | $87.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $341.9K |
| Free Cash FlowOCF − Capex | $-44.6M | $-479.7K |
| FCF MarginFCF / Revenue | -99.4% | -2.1% |
| Capex IntensityCapex / Revenue | 21.9% | 3.5% |
| Cash ConversionOCF / Net Profit | — | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $-1.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $341.9K | ||
| Q3 25 | $-52.6M | $-1.4M | ||
| Q2 25 | $-32.4M | $609.7K | ||
| Q1 25 | $-11.6M | $803.7K | ||
| Q4 24 | $-108.6M | $2.4M | ||
| Q3 24 | $-28.9M | — | ||
| Q2 24 | $-30.0M | $1.9M | ||
| Q1 24 | $-41.7M | — |
| Q4 25 | $-44.6M | $-479.7K | ||
| Q3 25 | $-61.5M | $-1.4M | ||
| Q2 25 | $-45.8M | $-171.2K | ||
| Q1 25 | $-22.2M | $293.1K | ||
| Q4 24 | $-187.0M | $1.2M | ||
| Q3 24 | $-47.4M | — | ||
| Q2 24 | $-50.1M | $869.4K | ||
| Q1 24 | $-65.8M | — |
| Q4 25 | -99.4% | -2.1% | ||
| Q3 25 | -687.0% | -6.3% | ||
| Q2 25 | -267.9% | -0.8% | ||
| Q1 25 | -524.0% | 1.5% | ||
| Q4 24 | -3702.8% | 5.5% | ||
| Q3 24 | -728.4% | — | ||
| Q2 24 | -683.8% | 4.2% | ||
| Q1 24 | -661.5% | — |
| Q4 25 | 21.9% | 3.5% | ||
| Q3 25 | 99.7% | 0.2% | ||
| Q2 25 | 78.2% | 3.6% | ||
| Q1 25 | 251.1% | 2.7% | ||
| Q4 24 | 1552.7% | 5.7% | ||
| Q3 24 | 284.6% | — | ||
| Q2 24 | 274.6% | 5.2% | ||
| Q1 24 | 242.5% | — |
| Q4 25 | — | 1.44× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 5.01× | ||
| Q1 25 | — | 1.85× | ||
| Q4 24 | — | 4.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.99× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
NTIC
| Inside The USA To Unaffiliated Customers | $7.5M | 32% |
| Natur Tec | $6.0M | 26% |
| Acobal | $3.6M | 15% |
| Other | $2.7M | 12% |
| BR | $2.1M | 9% |
| Zerust OY | $1.4M | 6% |
